MorphoSys' Unit To Intorduce Series Of Novel Anti-drug Antibodies - Quick Facts RTT News Starting with the recent launch of fully human, recombinant antibodies binding Rituximab and Trastuzumab, AbD Serotec intends to expand this product category with antibodies against Alemtuzumab, Bevacizumab, Infliximab, Ustekinumab, and Adalimumab in ... MORPHOSYS AG : AbD Serotec to Launch Panel of HuCAL Anti-Drug Antibodies ... |
